

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

Mouse Anti-CD154 Monoclonal Antibody, FITC Conjugated, Clone TRAP1

RRID:AB_396049

Type: Antibody

Proper Citation

BD Biosciences Cat# 555699, RRID:AB_396049

Antibody Information

URL: http://antibodyregistry.org/AB_396049

Proper Citation: BD Biosciences Cat# 555699, RRID:AB_396049

Target Antigen: CD154 (CD40 Ligand)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Mouse Anti-CD154 Monoclonal Antibody, FITC Conjugated, Clone TRAP1

Description: This monoclonal targets CD154 (CD40 Ligand)

Target Organism: baboon, cynomolgus, rhesus, human

Clone ID: TRAP1

Antibody ID: AB_396049

Vendor: BD Biosciences

Catalog Number: 555699

Record Creation Time: 20250819T223233+0000

Record Last Update: 20250820T023137+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-CD154 Monoclonal Antibody, FITC Conjugated, Clone TRAP1.

No alerts have been found for Mouse Anti-CD154 Monoclonal Antibody, FITC Conjugated, Clone TRAP1.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Akahata W, et al. (2023) Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study. Cell reports. Medicine, 4(8), 101134.

Nogimori T, et al. (2022) Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. Frontiers in immunology, 13, 1081047.

Schrottmaier WC, et al. (2022) Platelet p110?? mediates platelet-leukocyte interaction and curtails bacterial dissemination in pneumococcal pneumonia. Cell reports, 41(6), 111614.

Sulbaran G, et al. (2022) Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. Cell reports. Medicine, 3(2), 100528.

Ott PA, et al. (2020) A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 183(2), 347.